Isolated autosomal dominant hypomagnesemia, Glaudemans type

Isolated autosomal dominant hypomagnesemia, Glaudemans type (also known as HOMG2) is a rare inherited disorder of magnesium metabolism caused by mutations in the KCNA1 gene, which encodes the voltage-gated potassium channel Kv1.1. This gene plays a role in renal magnesium reabsorption, and pathogenic variants lead to excessive urinary magnesium wasting, resulting in persistently low serum magnesium levels (hypomagnesemia). The condition primarily affects the kidneys' ability to properly retain magnesium. Patients typically present with symptoms related to chronic hypomagnesemia, which can include muscle cramps, muscle weakness, tetany (involuntary muscle contractions), tremor, and fatigue. Some individuals may also experience seizures or cardiac arrhythmias if magnesium levels become critically low. Notably, this form of hypomagnesemia is considered 'isolated' because it is not typically accompanied by significant disturbances in other electrolytes such as calcium or potassium, distinguishing it from other hereditary magnesium-wasting disorders. The condition follows an autosomal dominant inheritance pattern, meaning a single copy of the mutated gene is sufficient to cause the disorder. Treatment is primarily supportive and involves lifelong oral magnesium supplementation to maintain adequate serum magnesium levels and prevent symptoms. In some cases, intravenous magnesium may be required during acute episodes of severe hypomagnesemia. Regular monitoring of serum magnesium levels is recommended. The prognosis is generally favorable with appropriate supplementation, though adherence to treatment is essential to prevent complications.

Common questions about Isolated autosomal dominant hypomagnesemia, Glaudemans type